VASCULITIS SYNDROMES: Edited by Hasan Yazici and Yusuf YaziciTakayasu arteritisEsatoglu, Sinem Nihala; Hatemi, GulenbAuthor Information aDepartment of Rheumatology, Gaziosmanpasa Training and Research Hospital bDepartment of Medicine, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey Correspondence to Sinem Nihal Esatoglu, MD, Department of Rheumatology, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey. E-mail: [email protected] Current Opinion in Rheumatology: January 2022 - Volume 34 - Issue 1 - p 18-24 doi: 10.1097/BOR.0000000000000852 Buy Metrics Abstract Purpose of review The purpose of this review is to summarize the recent advances in Takayasu arteritis (TAK), mainly focusing on pathogenesis, imaging modalities, and management. Recent findings Three novel clusters based on angiographic findings were identified in the Indian cohort and replicated in the North American cohorts. Different new imaging modalities have been tried in the assessment of arterial inflammation with promising results. There is more evidence on the long-term use of tocilizumab, but relapses are common. In light of the recent findings on the pathogenesis of TAK, Janus kinase inhibitors seem to be promising. Summary Improvement in imaging modalities and in our understanding of the disease pathogenesis will allow us to better assess the disease activity and identify effective therapeutic agents. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.